Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Short-Term Debt repayments (2022 - 2025)

Historic Short-Term Debt repayments for Gain Therapeutics (GANX) over the last 4 years, with Q3 2025 value amounting to $24996.0.

  • Gain Therapeutics' Short-Term Debt repayments rose 813.29% to $24996.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $94256.0, marking a year-over-year increase of 394.58%. This contributed to the annual value of $90879.0 for FY2024, which is 203.44% up from last year.
  • Gain Therapeutics' Short-Term Debt repayments amounted to $24996.0 in Q3 2025, which was up 813.29% from $24238.0 recorded in Q2 2025.
  • Over the past 5 years, Gain Therapeutics' Short-Term Debt repayments peaked at $37974.0 during Q1 2022, and registered a low of -$1363.0 during Q2 2022.
  • Over the past 4 years, Gain Therapeutics' median Short-Term Debt repayments value was $22579.0 (recorded in 2023), while the average stood at $22013.1.
  • Data for Gain Therapeutics' Short-Term Debt repayments shows a peak YoY increase of 173213.5% (in 2023) and a maximum YoY decrease of 4308.74% (in 2023) over the last 5 years.
  • Gain Therapeutics' Short-Term Debt repayments (Quarter) stood at $21582.0 in 2022, then grew by 4.62% to $22579.0 in 2023, then rose by 0.89% to $22780.0 in 2024, then increased by 9.73% to $24996.0 in 2025.
  • Its Short-Term Debt repayments was $24996.0 in Q3 2025, compared to $24238.0 in Q2 2025 and $22242.0 in Q1 2025.